K-877 + cyclosporine

K-877 + cyclosporine is a combination of **pemafibrate** (code name K-877; marketed as pemafibrate) and **cyclosporine**. Pemafibrate is a selective **peroxisome proliferator-activated receptor alpha (PPARα) modulator**, used primarily for the reduction of plasma triglycerides in hypertriglyceridemia patients, and is well-tolerated according to clinical studies. Cyclosporine is an immunosuppressive agent that inhibits **calcineurin**, primarily used to prevent transplant rejection, treat autoimmune disorders, and modulate immune responses. Combining these drugs may have potential pharmacokinetic interactions, including additive renal impairment and altered plasma concentrations due to cyclosporine’s inhibition of CYP3A4 and drug transporters[1][4][3]. No studies specifically address the efficacy or safety of this combination as a distinct therapeutic product.

Brand names

pemafibrate

Other names

pemafibrate + cyclosporine